

National Health (Pharmaceutical Benefits) (Pharmacist Substitution of Medicines without Prescription during Shortages) Amendment (No. 3) Determination 2024

I, Nikolai Tsyganov, as delegate of the Minister for Health and Aged Care, make the following determination.

Dated 13 May 2024

Nikolai Tsyganov Assistant Secretary Pricing and PBS Policy Branch Technology Assessment and Access Division Department of Health and Aged Care

Contents

1	Name	1
2	Commencement	1
3	Authority	1
4	Schedules	1
Schedule 1—Amer	adments	2

National Health (Pharmaceutical Benefits) (Pharmacist Substitution of Medicines without Prescription during Shortages) Determination 2021

National Health (Pharmaceutical Benefits) (Pharmacist Substitution of Medicines without Prescriptions during Shortages) Amendment (No.3) Determination 2024

1 Name

- (1) This instrument is the National Health (Pharmaceutical Benefits) (Pharmacist Substitution of Medicines without Prescription during Shortages) Amendment (No. 3) Determination 2024.
- (2) This instrument may also be cited as PB 51 of 2024.

2 Commencement

(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information				
Column 2	Column 3			
Commencement	Date/Details			
15 May 2024	15 May 2024			
	Column 2 Commencement			

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under subsection 89A(3) of the *National Health Act* 1953.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Pharmaceutical Benefits) (Pharmacist Substitution of Medicines without Prescription during Shortages) Determination 2021

1 Subsection 5(8)

Item	Column 1 Prescribed pharmaceutical benefit	Column 2 Substitute pharmaceutical benefit
1	Listed drug: Insulin degludec with insulin aspart Form: Injections, pre-filled pen, 70 units-30 units per mL, 3 mL, 5 Manner of administration: Injection Brand: Ryzodeg Flextouch	Listed drug: Insulin degludec with insulin aspart Form: Injections, cartridges, 70 units-30 units per mL, 3 mL, 5 Manner of administration: Injection Brand: Ryzodeg Penfill
2	Listed drug: Fluoxetine Form: Tablet, dispersible, 20 mg (as hydrochloride) Manner of administration: Oral Brand: Zactin Tablet	Listed drug: Fluoxetine Form: Capsule 20 mg (as hydrochloride) Manner of administration: Oral Brand: any of the following: (a) APO-Fluoxetine (b) BTC Fluoxetine (c) Blooms the Chemist Fluoxetine (d) FLUOTEX (e) Fluoxetine APOTEX (f) Fluoxetine Sandoz (g) Fluoxetine generichealth (h) NOUMED FLUOXETINE (i) Prozac 20 (j) Zactin
3	Listed drug: Fluoxetine Form: Tablet, dispersible, 20 mg (as hydrochloride) Manner of administration: Oral Brand: Zactin Tablet	Listed drug: Fluoxetine Form: Capsule 10 mg (Medreich) (S19A) Manner of administration: Oral Brand: Fluoxetine Capsules 10 mg (Medreich, UK)
4	Listed drug: Gliclazide Form: Tablet 30 mg (modified release) Manner of administration: Oral Brand: any of the following: a) APO-Gliclazide MR b) Gliclazide MR Viatris c) Pharmacor Gliclazide MR	Listed drug: Gliclazide Form: Tablet 60 mg (modified release) Manner of administration: Oral Brand: any of the following: a) ARDIX GLICLAZIDE 60mg MR b) Diamicron 60mg MR c) Gliclazide Lupin MR

Repeal the table, substitute:

2

National Health (Pharmaceutical Benefits) (Pharmacist Substitution of Medicines without Prescriptions during Shortages) Amendment (No.3) Determination 2024

d) Pharmacor Gliclazide MR

5	Listed drug: Abatacept	Listed drug: Abatacept
	Form: Injection 125 mg in 1 mL dose single dose pre-filled syringe	Form: Injection 125 mg in 1 mL single autoinjector
	Manner of administration: Injection	Manner of administration: Injection
	Brand: Orencia	Brand: Orencia ClickJect
Form: In	Listed drug: Abatacept	Listed drug: Abatacept
	Form: Injection 125 mg in 1 mL single dose	Form: Injection 125 mg in 1 mL single dose pre-
	autoinjector	filled syringe
	autoinjector Manner of administration: Injection	filled syringe Manner of administration: Injection